Amolyt Pharma is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma’s portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors.

Novo Ventures

Sham Innovation Santé

ATEM Capital Fund LP

Kurma Partners

EQT life science

Mass General Brigham Ventures

OrbiMed

Pontifax

Credit Agricole Entreprises

Eurazeo

Sectoral Asset Management

Bpifrance

Sofinnova Partners

Tekla Capital Management

Intermediate Capital Group

CTI Life Sciences Fund

Andera Partners

Amolyt Pharma

Microsoft Exchange Online

Office 365 Mail

Bunny Fonts

Choopa

Microsoft DNS

Constant Hosting

Marketing and Product

Divya Gupta

Business Management

Michael Culler

Sales and Support

Patrick Loustau

Consulting

Rakesh Datta

Raphaël Wisniewski

Roy Amariglio

Naveed Siddiqi

Toby Sykes

Cedric Moreau

Allan Gobbs

Thierry Laugel

Felice Verduyn

Mark Sumeray

Chief Medical Officer

Thierry Abribat

Founder & CEO

Louis J. Arcudi

Chief Financial Officer

Chief Scientific Officer

Medical Acquired Companies With More Than $1M in Revenue

Acquired Pharmaceutical Companies

Europe Companies (Top 10K)

Health Care Acquired Companies With Fewer Than 1000 Employees

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.

Series C - Amolyt Pharma

Series B - Amolyt Pharma

Venture Round - Amolyt Pharma

EQT Life Sciences

Series A - Amolyt Pharma

Écully

Rhone-Alpes

France

Europe

AstraZeneca in billion-dollar swoop

AstraZeneca Completes $1B Amolyt Pharma Takeover

AstraZeneca Closes Acquisition of Amolyt Pharma

AstraZeneca completes Amolyt Pharma acquisition

Acquisition of Amolyt Pharma completed

FDA Grants Fast Track Designation to Amolyt Pharma's Eneboparatide to Treat Hypoparathyroidism

Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism

AstraZeneca to Acquire Amolyt Pharma in Deal Worth Potentially $1.05 Billion

AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn

A therapeutic peptide in development for hypoparathyroidism, designed to produce sustained and stable levels of calcium in the blood.

A peptide growth hormone receptor antagonist in development for acromegaly, aimed at suppressing IGF1 levels.

A series of monoclonal antibodies targeting PTHR1, in preclinical evaluation for primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM).

United Kingdom

India

Asia

HTML5

F5 NGINX

Google Fonts

jQuery

Wordpress

Google Maps API

Facebook Comments

Comodo PositiveSSL Certificates

Ascendis Pharma is a biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases, including hypoparathyroidism.

Ascendis Pharma

Bridgebio is a biotechnology company dedicated to developing transformative therapies for genetic diseases, including hypoparathyroidism.

Bridgebio

Calcilytix Therapeutics is a biopharmaceutical company specializing in the development of novel therapies for endocrine disorders, including hypoparathyroidism.

Calcilytix Therapeutics

Amolyt Pharma is a biopharmaceutical company focused on developing treatments for hypoparathyroidism, a rare endocrine disorder. The company is developing eneboparatide, a novel parathyroid hormone receptor 1 (PTHR1) agonist, which has demonstrated promising results in clinical trials.

Director of Business Development

Associate Director, Business Development

Senior Manager Business Development and Alliance Management

Marketing Analyst

Research Assistant

Galenic Assistant

Camille Rivail

Head Of Finance

Directeur Administratif et Financier / CFO France

CFO / Directeur Administratif et Financier

Finance Director

Group Financial Controller

Accounting Manager

Business Analyst

European Reporting Analyst

Accounting Manager France, Belgium & Spain

European Accountant

Accountant

Head Of Finance at Amolyt Pharma

Benedicte Gagnere

Director Clinical Operations

Director, Clinical Operations

Clinical Project Manager - Galderma R&D

Researcher in Clinical Research

Director Clinical Operations at Amolyt Pharma

Nadege Tremel

Director of Project Management

Drug Development Project Manager

Pharmaceutical Development Project Manager

Pharmaceutical Development Project Leader

Research scientist

Postdoctoral fellow

Jean-Francois Dubuisson

Board Member

Non Executive Director

Executive Director CV Medical Strategy

VP Medical

Vice President Medical, Business Development

Vice President Clinical Development

Vice President Clinical Research

Medical Advisor

Specialist Registrar Cardiothoracic Surgery

BHF Junior Research Fellow

Chief Medical Officer at Amolyt Pharma

Mark Frcs

Scientific Founder, and Chairman of the Scientific Advisory Board

President

Vice President, Endocrinology Research

Assistant Director, Endocrinology Research

Postdoctoral Fellow - Neuroendocrinology

CSO for Amolyt Pharma.  Scientific founder and Chairman, Scientific Advisory Board for Tiburio Therapeutics

President and CEO at MILLENDO THERAPEUTICS

CFO & SVP of Operations

Prior Chairman

SVP of Finance & Operations

Director of International Finance and Commerical Operations

Int'l Finance Manager

Lou Arcudi

Chief Business Officer

SVP Global Commercialization Cardiovascular & Metabolics

SVP Global Marketing & Medical Affairs

VP Sales, Managed Health Care & Government Accounts

President & General Manager

Regional Business Director North East

Senior Director Marketing Diabetes

Project Leader Business Acceleration

Director Marketing

Product Manager

Sales Representative

Market Research & Business Development Manager

Human Resources & Training Manager

Chief Business Officer at Amolyt Pharma

Chief Development Officer (CDO)

VP portfolio management

Director, Business Development

Innovation director

Innovation manager

Business manager

Chief Development Officer at Amolyt Pharma

Thomas Delale

Manager (Gérant)

Member of the Board of Directors

Founder & CEO Amolyt Pharma

Director Medical Affairs

Associate Director Medical Affairs

Free Lance Consulting - Medical Affairs

Senior Medical Science Liaison - Multiple Sclerosis

Medical Science Liaison - Diabetes & Cardiovascular

Senior Regulatory Affairs Manager

Regulatory Affairs Manager

Senior Compliance Manager

Global Medical Affairs at Amolyt Pharma PharmD, MS, BCMAS

Blandine Weiss

Human Resources Director

VP of Human Resources

Human Resources Manager

Junior Executive Human Resources

Human Resource apprenticeship

Human Resources intern

Human Resources Director, Amolyt Pharma

Clementine Laurent

Senior Director Medical Affairs

Director, Medical Affairs

Medical Science Liaison

Medical Science Liaison - NeuroPsych & Pain

Manager, Global Technical Support

Field Applications Scientist

Post doctoral research associate

Medical Affairs │ Scientist │ Innovator │ Educator

Niccole Larsen

news impact assignment basic	general	May 6, 2024 7:49 AM	f6a99faf
public peers	general	May 6, 2024 7:49 AM	82ca2954
news daily refresh	general	Aug 31, 2024 12:20 PM	bd774c14
news processing daily refresh	general	Aug 29, 2024 3:40 PM	2822fbd7
news impact assignment daily	general	Aug 30, 2024 3:37 PM	1878bc77
news processing basic	general	May 6, 2024 7:49 AM	4b54f9cf
company summary	general	Aug 31, 2024 3:00 AM	dc53c725
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	d814ec5b
crunchbase profile	general	Nov 25, 2024 11:40 AM	0368c80d
li profile	general	May 6, 2024 7:49 AM	88a820a2
translate crunchbase fundingrounds	general	Nov 25, 2024 2:09 PM	c6b81c3d
peers	general
news basic	general	May 6, 2024 7:49 AM	d9a1d41c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AMOLYTPHARMA

Amolyt Pharma